Skip to content

Study · Randomized controlled trial · n = 120 · 2007

5 results

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE

Hepatology (Baltimore, Md.)1 Jan 2007Cited by 71 (Europe PMC)

PMID17187405 (opens in a new tab)DOI10.1002/hep.21468 (opens in a new tab)PepBankPUB-17187405
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced HCC, cumulative survival did not differ between octreotide and placebo.

    In plain wordsIn advanced liver cancer, cumulative survival did not differ between octreotide and placebo.

    Peptide
    Octreotide
    Outcome
    No significant changeCumulative survival
    Study

    n = 120

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Source sentences

    Summary
    There was no difference in the cumulative survival.
    1 context sentence
    Summary · context
    One hundred twenty untreated patients with histologically confirmed HCC were randomized to receive either long-acting octreotide (Sandostation LAR 30 mg) intramuscularly every 4 weeks or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced HCC, median survival was 4.7 months with octreotide versus 5.3 months with placebo.

    In plain wordsIn advanced liver cancer, median survival was numerically shorter with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMedian survival
    Study

    n = 120

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Median survival
    4.7 months
    octreotide group
    Median survival
    5.3 months
    control group

    Source sentences

    Summary
    The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group.
    1 context sentence
    Summary · context
    One hundred twenty untreated patients with histologically confirmed HCC were randomized to receive either long-acting octreotide (Sandostation LAR 30 mg) intramuscularly every 4 weeks or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced HCC, six-month survival was 41% with octreotide versus 42% with placebo.

    In plain wordsIn advanced liver cancer, six-month survival was numerically lower with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseSix-month survival
    Study

    n = 120

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Six-month survival rate
    41%
    octreotide group
    Six-month survival rate
    42%
    control group

    Source sentences

    Summary
    Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.
    1 context sentence
    Summary · context
    One hundred twenty untreated patients with histologically confirmed HCC were randomized to receive either long-acting octreotide (Sandostation LAR 30 mg) intramuscularly every 4 weeks or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In advanced HCC, octreotide's unadjusted mortality risk versus placebo was 1.11 (95% CI 0.76-1.63; P=0.59).

    In plain wordsIn advanced liver cancer, octreotide's mortality risk estimate was numerically higher than placebo, without statistical significance.

    Peptide
    Octreotide
    Outcome
    IncreaseUnadjusted mortality risk
    Study

    n = 120

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Unadjusted relative risk for mortality
    1.11 RR
    octreotide versus control
    95% CI of unadjusted relative risk for mortality
    0.76 to 1.63 RR
    octreotide versus control
    p-value
    0.59 p
    octreotide versus control

    Source sentences

    Summary
    The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59).
    1 context sentence
    Summary · context
    One hundred twenty untreated patients with histologically confirmed HCC were randomized to receive either long-acting octreotide (Sandostation LAR 30 mg) intramuscularly every 4 weeks or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In advanced HCC, octreotide's adjusted mortality risk versus placebo was 1.05 (95% CI 0.71-1.55; P=0.83).

    In plain wordsIn advanced liver cancer, adjusted mortality risk was numerically higher with octreotide than placebo, without statistical significance.

    Peptide
    Octreotide
    Outcome
    IncreaseAdjusted mortality risk
    Study

    n = 120

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 4 weeks · intramuscularAs given in this study (human).

    Measurements

    Adjusted relative risk of mortality, octreotide vs placebo
    1.05 relative risk
    adjusted for Okuda, CTP and CLIP scores
    95% CI of adjusted relative risk
    0.71 to 1.55 relative risk
    adjusted for Okuda, CTP and CLIP scores
    P value
    0.83 P
    adjusted relative risk

    Source sentences

    Summary
    When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83).
    1 context sentence
    Summary · context
    One hundred twenty untreated patients with histologically confirmed HCC were randomized to receive either long-acting octreotide (Sandostation LAR 30 mg) intramuscularly every 4 weeks or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.